Skip to content

To explore the protective effect of losartan on residual renal function in patients with continuous ambulatory peritoneal dialysis

To explore the protective effect of losartan on residual renal function in patients with continuous ambulatory peritoneal dialysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018948
Enrollment
Unknown
Registered
2018-10-17
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic renal failure

Interventions

Group 1:using no ACEI/ARB drugs
Group 2:using losartan 100mg
Group 3:using losartan 200mg

Sponsors

the Aflliliate Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) 120 cases of peritoneal dialysis at least one month were selected,regardless of gender and primary disease,whose age between 18 and 70.No additional cinicl trails were conducted within 3 months; (2) Residual renal function was assessed above 5mL/min/1.73m^2. Formula RRF= (renal urea clearance + renal creatinine clearance) /2; Renal urea clearance rate = (concentration of urine BUN/concentration of serum BUN) *24h urine volume /1440ml;Renal creatinine clearance = (urine creatinine concentration/blood creatinine concentration) *24h urine volume /1440ml; (3) 1.5% or 2.5% peritoneal dialysis fluid were used 3 to 5 times per day; (4) Blood pressure should be above 110/60mmHg with or without antihypertensive drugs; (5) If ACEI or ARB drugs were uesd recently,those should be discontinued for one month before enrollment; (6) Volunteer for this clinical trial study and sign informed consent.

Exclusion criteria

Exclusion criteria: With systemic infectious disease, recurrent peritonitis, congestive heart failure, serious heart valve disease, malignant hypertension,major vascular disease, recent six months had a myocardial infarction and cerebral infarction,chronic liver disease, malignant tumor,mental disorders, bilateral renal artery stenosis,allergic to ARB/ACEI.

Design outcomes

Primary

MeasureTime frame
residual renal function;ECT-GFR;urine volume;

Secondary

MeasureTime frame
serum creatinine;blood urea;

Countries

China

Contacts

Public ContactJiang Chunming

the Aflliliate Drum Tower Hospital of Nanjing University Medical School

guloujiang@sina.com+86 13815884488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026